Alector LLC

Abbvie Biotherapeutics Inc.

Patricia Culp

Arnon Rosenthal

Helen Lam

Wei-Hsien Ho

Andrew Pincetic

Seung-Joo Lee

Robert Pejchal

Kate Monroe

Nels P Nielson

David Powers

Yoshiko Akamatsu

Shiming Ye

Ping Y Huang

Leonard Presta

Charles M Forsyth

Alan F Wahl

Rashmi Bankoti

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-SIRPα antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-Siglec-5 antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-CD33 antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-Siglec-7 antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPβ1 polypeptide, e.g., a human SIRPβ1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-SIRP-Beta1 antibodies and methods of use thereof

Anti-SIRPa antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-siglec-5 antibodies and methods of use thereof

Anti-SIRPA antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.

Bispecific binding proteins that bind CD40 and mesothelin

Provided herein are compositions comprising monoclonal antibodies and antigen binding fragments thereof that bind TweakR and methods for their use in treating cancer.

Growing community of inventors

Oakland, CA, United States of America

Patricia Culp